Skip to main content

Venous Thromboembolism (VTE)

2
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

BEVYXXAApproved
betrixaban
Unknown Company
oral2017

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
BetrixabanPhase 31 trial
Active Trials
NCT01583218Completed7,513Est. Jan 2016
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
2 programs
EdoxabanPHASE_31 trial
EdoxabanPHASE_31 trial
Active Trials
NCT02798471Completed290Est. May 2022
NCT02073682Completed1,046Est. Sep 2017
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
Experimental: HyperslimPHASE_41 trial
Active Trials
NCT06958588RecruitingEst. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vera TherapeuticsExperimental: Hyperslim
Daiichi SankyoEdoxaban
Daiichi SankyoEdoxaban
AstraZenecaBetrixaban

Clinical Trials (4)

Total enrollment: 8,849 patients across 4 trials

NCT06958588Vera TherapeuticsExperimental: Hyperslim

Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis

Start: May 2025Est. completion: Mar 2026
Phase 4Recruiting
NCT02798471Daiichi SankyoEdoxaban

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Start: Mar 2017Est. completion: May 2022290 patients
Phase 3Completed
NCT02073682Daiichi SankyoEdoxaban

Cancer Venous Thromboembolism (VTE)

Start: Jul 2015Est. completion: Sep 20171,046 patients
Phase 3Completed
NCT01583218AstraZenecaBetrixaban

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Start: Mar 2012Est. completion: Jan 20167,513 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 8,849 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.